No abstract available
Keywords:
CRISPR/Cas9 screening; EGLN1; HIF1A; KRAS; Lung cancer.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma of Lung / drug therapy
-
Adenocarcinoma of Lung / genetics*
-
Adenocarcinoma of Lung / metabolism
-
Adenocarcinoma of Lung / pathology
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor*
-
Disease Management
-
Disease Susceptibility
-
Gene Knockout Techniques
-
Genomics* / methods
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Hypoxia-Inducible Factor-Proline Dioxygenases / genetics*
-
Hypoxia-Inducible Factor-Proline Dioxygenases / metabolism
-
Models, Biological
-
Molecular Targeted Therapy
-
Mutation*
-
Proto-Oncogene Proteins p21(ras) / genetics*
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
HIF1A protein, human
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
KRAS protein, human
-
EGLN1 protein, human
-
Hypoxia-Inducible Factor-Proline Dioxygenases
-
Proto-Oncogene Proteins p21(ras)